Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Other Non Operating Income: 2009-2024

Historic Other Non Operating Income for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Dec 2024 value amounting to -$670,000.

  • Lineage Cell Therapeutics' Other Non Operating Income fell 51.12% to $219,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 32.23%. This contributed to the annual value of -$670,000 for FY2024, which is 23.16% down from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Other Non Operating Income of -$670,000 as of FY2024, which was down 23.16% from -$544,000 recorded in FY2023.
  • Lineage Cell Therapeutics' 5-year Other Non Operating Income high stood at -$544,000 for FY2023, and its period low was -$3.8 million during FY2020.
  • Over the past 3 years, Lineage Cell Therapeutics' median Other Non Operating Income value was -$670,000 (recorded in 2024), while the average stood at -$1.1 million.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Other Non Operating Income crashed by 249.37% in 2020, and later spiked by 74.72% in 2023.
  • Over the past 5 years, Lineage Cell Therapeutics' Other Non Operating Income (Yearly) stood at -$3.8 million in 2020, then soared by 39.21% to -$2.3 million in 2021, then rose by 6.39% to -$2.2 million in 2022, then skyrocketed by 74.72% to -$544,000 in 2023, then decreased by 23.16% to -$670,000 in 2024.